MicroStockProfit.com releases investment report on AEterna Zentaris

Apr 20 2010

MicroStockProfit.com announces an investment report featuring AEterna Zentaris Inc. (Nasdaq:AEZS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/AEZS

AEterna Zentaris Inc. (AEZS) is a global biopharmaceutical company focused on endocrine therapy and oncology. The Company's product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The products of the Company include Cetrorelix, AEZS-108, Perifosine, Ozarelix, AEZS-112 and AEZS-130. On March 31, 2008, the Company completed the selling of its product Impavido to Paladin Labs Inc. (Paladin). On March 5, 2009, the Company entered into a development, commercialization and license agreement with sanofi-aventis for the development, registration and marketing of Cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market. 

Message Board Search for AEZS: http://www.boardcentral.com/boards/AEZS

In the report, the analyst notes:

"AEZS, a late-stage drug development company specializing in oncology and endocrinology, announced recently that it has received commitments from institutional investors to purchase US$15 million of securities in a registered direct offering. Under the terms of a Securities Purchase Agreement, the Company will sell to such institutional investors an aggregate of approximately 11.1 million common shares of its capital at a price of US$1.35 per share and issue warrants to acquire an aggregate of approximately 4.4 million common shares at an exercise price of US$1.50 per share. 

"AEZS recently announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated phase 3 programs for the development of its lead anticancer compound, Perifosine, in its two lead indications, multiple myeloma and refractory advanced colorectal cancer. Previously, agreement was reached with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the pivotal studies in each of the lead indications ... "